RESEARCH AND DEVELOPMENT
Research and development of new vaccines
Since its inception, BIOPHARMA has been actively engaged in the development of new vaccines utilizing strains isolated locally, including vaccines for diseases such as Blue Tongue, Epizootic Haemorrhagic Disease (EHD), and avian diseases. These efforts have significantly contributed to Morocco’s ability to combat and control, and in some cases eradicate, several animal diseases. The development of these vaccines has garnered recognition from international animal health authorities, thereby facilitating trade with various countries worldwide.
.
In 2019, BIOPHARMA’s commitment to innovation and research was further acknowledged when it received the second prize of the “Grand Prix – Hassan II” for Invention and Research in the Agricultural Field. This prestigious accolade was awarded in the category of inventions and practical techniques, specifically for the development of a vaccine against Low Pathogenic Avian Influenza H9N2. Notably, this vaccine was derived from a wild strain isolated within the national territory, highlighting BIOPHARMA’s ability to harness local resources and expertise to address critical health challenges.
The recognition received by BIOPHARMA through the “Grand Prix – Hassan II” underscores the company’s dedication to advancing scientific innovation and contributing to the agricultural and veterinary sectors. By developing novel vaccines and practical solutions tailored to the needs of Morocco’s agricultural community, BIOPHARMA continues to play a pivotal role in enhancing animal health, promoting food security, and bolstering Morocco’s position in global trade and collaboration in the field of veterinary medicine.
